J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Prior to this announcement, Novartis' dividend was comfortably covered by both cash flow and earnings. This indicates that a ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities ...

Novartis Indias NEST competition culminates in a showcase of innovative healthcare solutions, highlighting the talent of young entrepreneurs.